Nucleic Acid Therapeutics Market Size is valued at USD 4.93 billion in 2023 and is predicted to reach USD 13.86 billion by the year 2031 at a 13.8% CAGR during the forecast period for 2024-2031.
Nucleic acid therapeutics stands for a group of medicinal interventions that prevent illness by means of nucleic acids. Cutting-edge and focused therapies for a broad spectrum of hereditary and chronic diseases are now available through gene-targeting therapies. These therapies can fix mutations, regulate gene expression, and silence dangerous genes. Rising rates of chronic diseases and genetic conditions have prompted an upsurge of studies into ways to improve healthcare systems around the world, which bodes well for the sector. Additionally, the nucleic acid therapeutics business is being propelled forward by rising demand for pharmaceuticals and healthcare services, as well as new developments in biological goods and DNA therapies. However, strict rules regarding nucleic acid therapeutics are anticipated to impede the expansion of this industry. The ongoing development of novel and improved nucleic acid therapeutics is propelling market expansion.
However, due to the high treatment costs, stringent regulatory constraints, and a general lack of knowledge of nucleic acid treatments among both patients and healthcare professionals, the nucleic acid therapeutics industry is expected to slow down market growth. The rapid advancement of research and development, the increased focus on the efficacy of mRNA vaccines, and the surge in investment and interest in nucleic acid-based treatments for infectious diseases were all beneficial effects of the COVID-19 pandemic for the nucleic acid therapeutics business. Furthermore, the demand for nucleic acid therapeutics is expected to rise due to innovative treatments receiving substantial funding from pharmaceutical firms and governments.
Competitive Landscape
Some Major Key Players In The Nucleic Acid Therapeutics Market:
- Novartis
- Moderna Inc
- BioNTech
- Arrowhead Pharmaceuticals
- Merck
- Thermo Fischer Scientific
- Sanofi
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- Qiagen
- Imugene
- Copernicus Therapeutics Inc.
- Protagonist Therapeutics
- Arbutus Biopharma
- Agilent Technologies
- Silence Therapeutics (UK),
- Astellas Pharma Inc. (Japan),
- CureVac SE (Germany),
- Sirnaomics (US),
- Arcturus Therapeutics Inc. (US)
- Other Market Players
Market Segmentation:
The nucleic acid therapeutics market is segmented based on technology, application, and end-user. By technology, the market is segmented into RNA-targeted therapeutics, gene therapies, epigenetic and microRNA-modulating therapies, genome editing therapies, and others. By application, the market is segmented into autoimmune disorders, genetic disorders, infectious diseases, cancer, and others. As per the end-user segment, the market is categorized into hospitals and clinics, academic & research institutes, and others.
Based On The Technology, The RNA Targeted Therapeutics Nucleic Acid Therapeutics Segment Is Accounted As A Major Contributor To The Nucleic Acid Therapeutics Market.
The RNA targeted therapeutics nucleic acid therapeutics category is expected to report a large global market share in 2023 due to its precision in targeting and modulating gene expression, notable progress in RNA technology, a surge in financing for RNA-based research, and the effective creation and authorization of RNA-based therapeutics for a range of illnesses, including gene diseases and viral infections.
Hospitals & Clinics Segment To Witness A Rapid Growth.
The hospitals & clinics market is expected to grow rapidly in the nucleic acid therapeutics market because of the improved healthcare infrastructure, the ability of these facilities to deliver specialized care and efficiently administer complex medications, the increasing frequency of genetic and chronic diseases, and the increasing use of modern genetic treatments, which is growing the hospital & clinics segment growth.
In The Region, The North American Nucleic Acid Therapeutics Market Holds A Significant Revenue Share.
The North American nucleic acid therapeutics market is estimated to register the maximum market share in revenue in the near future due to its state-of-the-art healthcare system, innovative treatments being readily available, and major expenditures on R&D by the pharmaceutical industry. The use of nucleic acid therapeutics is further encouraged by an increase in patient and healthcare provider understanding and comfort with these treatments. In addition, the Asia-Pacific region is expected to grow quickly in the global nucleic acid therapeutics market because of favourable government programs, a surge in investments in biotechnology, an uptick in genetic abnormalities, and a general increase in knowledge about cutting-edge medical therapies, which is growing the market demand in this area.
Recent Developments:
- In April 2024, Arrowhead Pharmaceuticals, Inc. announced the dosing of its investigational RNA interference (RNAi) therapeutic, ARO-CFB, in a Phase 1/2a clinical trial. The trial included up to sixty-six healthy volunteers and patients with complement-mediated kidney disease.
- In Aug 2022, Merck and Orna Therapeutics entered into a collaboration agreement to jointly explore, create, and market various initiatives, such as vaccines and treatments, in the fields of infectious disease and oncology.
Nucleic Acid Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.97 Bn |
|
Revenue Forecast In 2031 |
USD 13.86 Bn |
|
Growth Rate CAGR |
CAGR of 13.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Technology, Application, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis, Moderna Inc, BioNTech, Arrowhead Pharmaceuticals, Merck, Thermo Fischer Scientific, Sanofi, Alnylam Pharmaceuticals, Sarepta Therapeutics, Qiagen, Imugene, and Copernicus Therapeutics Inc. and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
